Drug Profile
Meningococcal vaccine groups A C Y W-135 conjugate - Yuxi Walvax Biotechnology
Alternative Names: Group ACYW135 meningococcal polysaccharide vaccine - Walvax; Ingovax ACWY; Walvax MPV ACYW® vaccineLatest Information Update: 28 Aug 2021
Price :
$50
*
At a glance
- Originator International Centre for Diarrhoeal Disease Research; Walvax Biotechnology
- Developer Incepta Vaccine; Walvax Biotechnology
- Class Conjugate vaccines; Meningococcal vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Meningococcal infections
Most Recent Events
- 28 Aug 2021 No recent reports of development identified for phase-I development in Meningococcal-infections(In adolescents, In children, In infants, Prevention, In volunteers, In adults) in China (SC, Injection)
- 28 Nov 2019 Walvax Biotechnology completes a phase I trial in Meningococcal Infections (In infants, In childrens, In adolescents, In adults, In volunteers, Prevention) in China (SC) (NCT04236960)
- 19 Mar 2018 International Centre for Diarrhoeal Disease Research, Bangladesh and Incepta Vaccine completes a phase II/III trial for Meningococcal infections (Prevention, In adults) in Bangladesh (SC) (NCT03263403)